Anti-idiotype antibodies in cancer treatment

77.9K

views

39

authors

12

articles

Anti-idiotype antibodies in cancer treatment

77.9K

views

39

authors

12

articles

Editorial

26 February 2013

Anti-idiotype antibodies in cancer treatment

Daniel E. Gomez

,

Ana M. Vázquez

,

Daniel F. Alonso

and

Amparo Macías

6,535 views

4 citations

Editors

4

Daniel E. Gomez

National University of Quilmes

Ana María Vázquez

Center of Molecular Immunology (Cuba)

Daniel F Alonso

National University of Quilmes

Center of Molecular Immunology (Cuba)

Impact

About

Actively induced immunotherapy is one of the most promising fields in cancer research and numerous approaches are being studied to design effective cancer vaccines. Among the treatment strategies to develop an effective immune response against tumor associated antigens is the use of anti idiotype (Ab2) mAb as antigen surrogates. Several studies in animal models have demonstrated the efficacy of these vaccines for triggering the immune system to induce specific and protective immunity against tumors of different origin. In fact, anti-idiotypic mAbs have been used successfully in cancer therapeutics to overcome the poor immunogenicity of some tumor-associated antigens, in particular those of non-protein origin. In some clinical trials, including patients with different tumors, anti-Id specific humoral and/or cellular responses following immunization were associated with improved clinical outcome.
This number of Frontiers will be dedicated to anti- idiotypic antibodies and their use in cancer treatment. Different article types will be considered: original contributions, case reports, methods, hypothesis and theory, reviews, historical, etc.

Actively induced immunotherapy is one of the most promising fields in cancer research and numerous approaches are being studied to design effective cancer vaccines. Among the treatment strategies to develop an effective immune response against tumor associated antigens is the use of anti idiotype (Ab2) mAb as antigen surrogates. Several studies in animal models have demonstrated the efficacy of these vaccines for triggering the immune system to induce specific and protective immunity against tumors of different origin. In fact, anti-idiotypic mAbs have been used successfully in cancer therapeutics to overcome the poor immunogenicity of some tumor-associated antigens, in particular those of non-protein origin. In some clinical trials, including patients with different tumors, anti-Id specific humoral and/or cellular responses following immunization were associated with improved clinical outcome.
This number of Frontiers will be dedicated to anti- idiotypic antibodies and their use in cancer treatment. Different article types will be considered: original contributions, case reports, methods, hypothesis and theory, reviews, historical, etc.

Download ebook

Share

Editors

Daniel E. Gomez

National University of Quilmes

Ana María Vázquez

Center of Molecular Immunology (Cuba)

Daniel F Alonso

National University of Quilmes

Center of Molecular Immunology (Cuba)

Impact

77,872 Total views

60,357 Article views

14,816 Article downloads

2,699 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

Cancer Immunity and Immunotherapy

Journal Thumbnail

Frontiers in Immunology

Cancer Immunity and Immunotherapy

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic